NCT07330050 2026-01-09
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
Clinical Trials
4 trialsNCT03648697 2020-08-11
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
Fujian Cancer Hospital
Phase 2 Unknown
NCT03003728 2020-07-10
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
University of Arkansas
Phase 2 Withdrawn
NCT01186809 2019-01-23
CIK2
A.O. Ospedale Papa Giovanni XXIII
Phase 2 Completed